EA202190132A1 - A PREPARATION FOR SUPPRESSING THE RECURRENCE OF HEMATOLOGICAL MALIGNANT TUMOR IN PATIENTS UNDER HEMOPOETIC STEM CELL TRANSPLANTATION - Google Patents

A PREPARATION FOR SUPPRESSING THE RECURRENCE OF HEMATOLOGICAL MALIGNANT TUMOR IN PATIENTS UNDER HEMOPOETIC STEM CELL TRANSPLANTATION

Info

Publication number
EA202190132A1
EA202190132A1 EA202190132A EA202190132A EA202190132A1 EA 202190132 A1 EA202190132 A1 EA 202190132A1 EA 202190132 A EA202190132 A EA 202190132A EA 202190132 A EA202190132 A EA 202190132A EA 202190132 A1 EA202190132 A1 EA 202190132A1
Authority
EA
Eurasian Patent Office
Prior art keywords
recurrence
stem cell
cell transplantation
suppressing
preparation
Prior art date
Application number
EA202190132A
Other languages
Russian (ru)
Inventor
Клаудиа Коррадо
Кристоф Бухер
Жюли Джоунс
Петер Гергели
Original Assignee
Прайотера Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Прайотера Лимитед filed Critical Прайотера Лимитед
Priority claimed from PCT/JP2019/029524 external-priority patent/WO2020022507A1/en
Publication of EA202190132A1 publication Critical patent/EA202190132A1/en

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Фармацевтический препарат, который подавляет рецидив гематологических злокачественных опухолей и/или улучшает показатель выживаемости пациентов, перенесших трансплантацию гемопоэтических стволовых клеток для лечения гематологических злокачественных опухолей, содержащий 2-амино-2-[4-(3-бензилоксифенилтио)-2-хлорфенил]этилпропан-1,3-диол или его фармацевтически приемлемую соль в качестве активного ингредиента.A pharmaceutical preparation that suppresses the recurrence of hematological malignant tumors and / or improves the survival rate of patients undergoing hematopoietic stem cell transplantation for the treatment of hematological malignant tumors, containing 2-amino-2- [4- (3-benzyloxyphenylthio) -2-chlorophenyl] ethylpropane- 1,3-diol or a pharmaceutically acceptable salt thereof as an active ingredient.

EA202190132A 2019-02-28 2019-07-26 A PREPARATION FOR SUPPRESSING THE RECURRENCE OF HEMATOLOGICAL MALIGNANT TUMOR IN PATIENTS UNDER HEMOPOETIC STEM CELL TRANSPLANTATION EA202190132A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019036598 2019-02-28
PCT/JP2019/029524 WO2020022507A1 (en) 2018-07-27 2019-07-26 Agent for inhibiting recurrence of hematological malignancy in patients who have undergone hematopoietic stem cell transplantation

Publications (1)

Publication Number Publication Date
EA202190132A1 true EA202190132A1 (en) 2021-05-21

Family

ID=76160099

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190132A EA202190132A1 (en) 2019-02-28 2019-07-26 A PREPARATION FOR SUPPRESSING THE RECURRENCE OF HEMATOLOGICAL MALIGNANT TUMOR IN PATIENTS UNDER HEMOPOETIC STEM CELL TRANSPLANTATION

Country Status (1)

Country Link
EA (1) EA202190132A1 (en)

Similar Documents

Publication Publication Date Title
PH12019550248A1 (en) Covalent inhibitors of kras
MX2021004639A (en) Combinations of lsd1 inhibitors for use in the treatment of solid tumors.
MX2018000777A (en) Substituted quinazoline compounds and their use as inhibitors of g12c mutant kras, hras and/or nras proteins.
EA201201186A1 (en) USE OF ERBB3 INHIBITORS IN THE TREATMENT OF NEGATIVE AND BASAL-LIKE BREAST CANCER TREATMENT
MX2019012884A (en) Combination therapy.
MX2021001807A (en) Combination of histone deacetylase inhibitor and protein kinase inhibitor and pharmaceutical use thereof.
MX2022004137A (en) Methods of treating fabry patients having renal impairment.
BR112016008016B8 (en) kras g12c inhibitory compounds, pharmaceutical composition comprising said compounds, methods for regulating the activity and for preparing a kras, hras or nras g12c mutant protein, method for inhibiting the proliferation of a population of cells and therapeutic uses of said compounds
PH12020551597A1 (en) Treatment of hidradenitis suppurativa using jak inhibitors
MX2017012125A (en) Method for promoting hair growth and preventing hair loss of patient, composition therefor, and method for preparing composition.
MX2017011633A (en) Use of mk2 inhibitor peptide-containing compositions for treating non-small cell lung cancer with same.
RU2018135973A (en) PHARMACEUTICAL COMBINATION CONTAINING METROFORMIN AND DYHYDROQUERCENINE, AND ITS APPLICATION FOR TREATING CANCER
MX2021001039A (en) Agent for inhibiting recurrence of hematological malignancy in patients who have undergone hematopoietic stem cell transplantation.
BR112021025764A2 (en) Pyrimidine derivative that inhibits the growth of cancer cells and medicinal use thereof
WO2016163799A3 (en) Pharmaceutical composition for treating cancer including 2-methoxy-4-(3-(4-methoxyphenyl)prop-1-en-1-yl)phenol as active ingredient
WO2017098051A3 (en) Combined preparations of pkm2 modulators and hmgb1
EA202091082A1 (en) COMPOSITION AND METHOD FOR TREATMENT OF PERIPHERAL T-CELL LYMPHOMA AND SKIN T-CELL LYMPHOMA
JPWO2020022507A5 (en)
MX2021003606A (en) Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases.
EA201791895A1 (en) DOSES AND METHODS OF ADMINISTRATION TELAVANCIN
EA202190132A1 (en) A PREPARATION FOR SUPPRESSING THE RECURRENCE OF HEMATOLOGICAL MALIGNANT TUMOR IN PATIENTS UNDER HEMOPOETIC STEM CELL TRANSPLANTATION
EA202191165A1 (en) ELACESTRANT IN COMBINATION WITH ABEMACYCLIBUS IN WOMEN WITH BREAST CANCER
EA201991069A1 (en) COMBINED THERAPY INHIBITOR OF PHOSPHOINOSITIDE-3-KINASE AND BINDING ZINC AGENT
BR112015012497A8 (en) pharmaceutical combinations and compositions, their uses, combined preparation, and commercial packaging
MX2020002336A (en) Lipolytic composition containing phosphocholine derivatives.